SCA2 knockout animal and methods of use

Details SCA2 knockout animal and methods of use SCA2 knockout animal and methods of use

2002-05-07

2008-11-04

Falk, Anne-Marie (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S013000, C800S014000

Reexamination Certificate

active

07446239

ABSTRACT:
The invention provides a mutant non-human mammal having a disrupted SCA2 gene, in particular, a mutant mouse having a disrupted SCA2 gene. The invention also provides methods of identifying a therapeutic agent for use in treating obesity or memory impairment by administering a compound to the mutant non-human mammal having a disrupted SCA2 gene and screening said mutant non-human mammal for reduced obesity, thereby identifying a therapeutic agent for use in treating obesity.

REFERENCES:
patent: 5175384 (1992-12-01), Krimpenfort et al.
patent: 5602299 (1997-02-01), Lazzarini
patent: 5859311 (1999-01-01), Albers et al.
patent: 6037521 (2000-03-01), Sato et al.
patent: 6066778 (2000-05-01), Ginsburg et al.
patent: 6194171 (2001-02-01), Pulst et al.
patent: 6251589 (2001-06-01), Tsuji et al.
patent: 6355690 (2002-03-01), Tsuji
patent: 6515197 (2003-02-01), Pulst et al.
patent: WO 97/42314 (1997-11-01), None
patent: WO 00/12710 (2000-03-01), None
Bradley et al. (1992) Modifying the mouse: Design and desire. Bio/Technology 10: 534-539.
Campbell and Wilmut (1997) Totipotency and multipotentiality of cultured cells: Applications and progress. Theriogenology 47: 63-72.
Doetschman, T. (1999) Interpretation of phenotype in genetically engineered mice. Laboratory Animal Science 49(2): 137-143.
Donehower et al. (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Molecular Carcinogenesis 14: 16-22.
Huynh et al. (Sep. 2000) Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nature Genetics 26: 44-50.
Jacks et al. (1992) Effects of an Rb mutation in the mouse. Nature 359: 295-300.
Jaenisch et al. (1988) Transgenic Animals. Science 240: 1468-1474.
Kuehn et al. (1987) A potential animal model for Lesch-Nyhan syndrome through introduction of HPRT mutations into mice. Nature 326: 295-298.
Moens et al. (1993) Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. Development 119: 485-499.
Mullins et al. (1996) Transgenesis in the rate and larger mammals. J. Clin. Invest. 97(7): 1557-1560.
Petridou et al. (2003) Heterogeneous inducible mammary-specific expression of JAB/SOCS1 in lactating transgenic mice is associated with no obvious phenotype, even at the cellular level. Transgenic Research 12: 693-706.
Sigmund, CD (2000) Viewpoint: Are studies in genetically altered mice out of control? Arterioscler. Thromb. Vasc. Biol. 20: 1425-1429.
Burright et al., “SCA1 Transgenic Mice: A Model for Neurodegeneration Caused by an Expanded CAG Trinucleotide Repeat,”Cell82:937-948 (1995).
Cha et al., “Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease,”Phil. Trans. R. Soc. Lond. B. 354:981-989 (1999).
Chai et al., “Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro,”Hum. Mol. Genet. 8:673-682 (1999).
Clark et al., “Purkinje Cell Expression of a Mutant Allele ofSCA1in Transgenic Mice Leads to Disparate Effects on Motor Behaviors, Followed by a Progressive Cerebellar Dysfunction and Histological Alterations,”J. Neurosci. 17:7385-7395 (1997).
Cummings et al., “Mutation of Eg-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology inSCA1Mice,”Neuron24:879-892 (1999).
Cummings et al., “Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1,”Nature Genet. 19:148-154 (1998).
David et al., “Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion,”Nature Genet. 17:65-70 (1997).
Davies et al., “Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation,”Cell90:537-548 (1997).
GenBank: Accession No. AA002843.
GenBank: Accession No. AF041472.
GenBank: Accession No. AF223576.
GenBank: Accession No. AK006480.
GenBank: Accession No. AK008433.
GenBank: Accession No. AK012370.
GenBank: Accession No. Aw258842.
GenBank: Accession No. L04961.
GenBank: Accession No. NM—024188.
GenBank: Accession No. NM—133362.
GenBank: Accession No. U70323.
GenBank: Accession No. U70670.
Gutekunst et al., “Nuclear and Neuropil Aggregates in Huntington's Disease: Relationship to Neuropathology,”J. Neurosci. 19:2522-2534 (1999).
Hodgson et al., “A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxocity, and Selective Striatal Neurodegeneration,”Neuron23:181-192 (1999).
Hogan et al.,Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1986).
Holmberg et al., “Spinocerebellar ataxia type 7 (SCA7) : a neurodegenerative disorder with neuronal intranuclear inclusions,”Hum. Mol. Genet. 7:913-918 (1998).
Huntington's Disease Collaborative Research Group, “A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes,”Cell72:971-983 (1993).
Huynh et al., “Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human,”Nature Genet. 26:44-50 (2000).
Huynh et al., “Expression of Ataxin-2 in Brains from Normal Individuals and Patients with Alzheimer's Disease and Spinocerebellar Ataxia 2,”Ann. Neurology45:232-241 (1999).
Igarashi et al., “Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch,”Nature Genet. 18:111-117 (1998).
Ikeda et al., “Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo,”Nature Genet. 13:196-202 (1999).
Imbert et al., “Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats,”Nature Genet. 14:285-291 (1996).
Ishikawa et al., “Abundant expression and cytoplasmic aggregation of α1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6,”Hum. Mol. Genet. 8:1185-1193 (1999).
Kawaguchi et al., “CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1,”Nature Genet. 8:221-228 (1994).
Kiehl et al., “The Ortholog of Human Ataxin-2 is Essential for Early Embryonic Patterning inC. elegans,” J. Mol. Neurosci. 15:231-41 (2000).
Kim et al., “Mutant Huntingtin Expression in Clonal Striatal Cells: Dissociation of Inclusion Formation and Neuronal Survival by Caspase Inhibition,”J. Neurosci. 19:964-973 (1999).
Klement et al., “Ataxin-1 Nuclear Localization and Aggregation: Role in Polyglutamine-Induced Disease in SCA1 Transgenic Mice,”Cell95:41-53 (1998).
Koeppen A., “The Purkinje Cell and its Afferents in Human Hereditary Ataxia,”Neuropathol. Exp. Neurol. 50:505-514 (1991).
Koide et al., “Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA),”Nature Genet. 6:9-13 (1994).
Koyano et al., “Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study,”Neurosci. Lett. 273: 117-120 (1999).
Kozlov et al., “Structure and function of the C-terminal PABC domain of human poly (A) -binding protein,”Proc. Natl. Acad. Sci. USA 98:4409-13 (2001).
Kuemmerle et al., “Huntington Aggregates May Not Predict Neuronal Death in Huntington's Disease,”Annals of Neurology46:842-849 (1999).
La Spada et al., “Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy,”Nature352:77-79 (1991).
Lippa et al., “Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease

Affiliated with

Also associated with

Rating

SCA2 knockout animal and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with SCA2 knockout animal and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SCA2 knockout animal and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4043407